Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 2,550 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neurodevelopmental Disorder Clear all

Conditions: Autism Spectrum Disorder
Interventions: SDARI-YA, AYA; Behavioral · Other
Lead sponsor: Drexel University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Autism
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: Anagnostou, Evdokia, M.D.; Individual
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Autism Spectrum Disorders, Psychosis, Fragile X Syndrome
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 3 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Attention Deficit Hyperactivity Disorder, Stimulant Use, Working Memory, Change in Sustained Attention, Mood
Interventions: Adderall IR 10mg, Placebo; Drug
Lead sponsor: University of Wyoming; Other
Eligibility: 18 Years to 29 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Laramie, Wyoming

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 20
States / cities: Dothan, Alabama • Anaheim, California • Imperial, California + 17 more

Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions: Specimen sample; Diagnostic Test
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Autism
Interventions: Aripiprazole, Placebos; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 5 Years to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Autism, Infant Development
Interventions: EarliPoint Investigational Device; Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: 8 Months to 10 Months
Enrollment: 2,120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions: dasotraline, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Newport Beach, California • Bradenton, Florida • Maitland, Florida + 5 more

Conditions: Autistic Disorder
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 30 Months to 58 Months
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: Attention Deficit/Hyperactivity Disorder (ADHD)
Interventions: Vyvanse, Behavioral Parent Training, Methylphenidate; Drug · Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 21 Years to 55 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Autism Spectrum Disorder, Insomnia
Interventions: COGMUSE-AUT; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Intellectual Disability, Mild to Moderate
Interventions: Cooking Skills, Physical Activity; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Amphetamine and/or methylphenidate, Hold stimulant medication; Drug · Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 2 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: ADHD, Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate, Atomoxetine; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 7 Years to 12 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Autism Spectrum Disorder, Autistic Disorder, Autism, Asperger's Syndrome, Pervasive Development Disorders
Interventions: Folinic Acid and placebo, Folinic Acid; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 3 Years to 14 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Autism, Aggression, Bipolar Disorder, Psychotic Disorders
Interventions: Family Navigator consultation; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 2 Years to 15 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autism Spectrum Disorder
Interventions: Hip-Hop Dance; Behavioral
Lead sponsor: Loma Linda University; Other
Eligibility: 7 Years to 11 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Autism Spectrum Disorder
Interventions: Help is in Your Hands; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 6 Months to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2033
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Intellectual Disability
Interventions: Physical Literacy & Food Literacy Intervention.; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 12 Years to 16 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Attention Deficit Hyperactivity Disorder, ADHD
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 6 Years to 12 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neurodevelopmental Abnormality
Interventions: Randomized to Umbilical Cord Milking at birth, Randomized to Delayed Cord Clamping at birth; Procedure
Lead sponsor: Sharp HealthCare; Other
Eligibility: 22 Months to 42 Months
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 15
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 10 more

Conditions: Cognitive Change
Interventions: Nongamified N-back training, Gamified N-back training, Multiple Domain Training, Coaching Session; Behavioral
Lead sponsor: Northeastern University; Other
Eligibility: 12 Years to 17 Years
Enrollment: 780 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Premature Birth, Premature Infant, Premature, Intrauterine Growth Restriction, Small for Gestational Age at Delivery
Interventions: PEAPOD Infant Body Composition measuring device; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 22 Weeks to 32 Weeks
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Social Groups for Autistic Young Adults (SDARIYA)

An fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism

Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment

Acute Effects of Stimulant Medication in College Students With ADHD

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children

Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

Early Intervention With Fluoxetine in Autism

Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)

Novel Adaptive Cognitive Training in Autistic Adults With Co-occurring Insomnia

Cooking Classes for Young Adults With ID

Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD)

Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

A Folinic Acid Intervention for Autism Spectrum Disorders

The Family VOICE Study

Exploring the Effectiveness of Dance as an Intervention to Promote Social-Emotional Health in Children With Autism Spectrum Disorder (ASD)

Evaluating the Impact of Telehealth-Based ASD Assessments and Supports on Child and Caregiver Outcomes

New Skills - No Scores Research Study

Genetic Measurements in Blood Cells of Children Taking Adderall or Methylphenidate

Two Year Developmental Follow-up for PREMOD2 Trial (Premature Infants Receiving Milking or Delayed Cord Clamping)

Executive Function Training for Children and Adolescents

Growing Little PEAPODS Study